Janssen acquires rights to depression therapy from Cerecor

Janssen has agreed a deal to purchase the rights to a major depressive disorder therapy from Cerecor.

The firm has acquired all of its rights to CERC-501 for initial gross proceeds of $25 million (19.36 million pounds), with $3.75 million deposited into a 12-month escrow, with a potential future $20 million regulatory milestone payment also agreed.

This potent and selective oral kappa opioid receptor antagonist has been developed as an adjunctive treatment of major depressive disorder and substance use disorders. It has shown potential in animal tests and has been generally well-tolerated in five human clinical trials.

Under the terms of the agreement, Janssen will assume the ongoing clinical trials and be responsible for any new development and commercialisation activities for CERC-501.

Dr Uli Hacksell, president, chief executive officer and chairman of Cerecor, said he believes "the neuroscience expertise and strength of Janssen will be instrumental in achieving the full medical and commercial potential of CERC-501".

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.